[ETRM] EnteroMedics Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Biotechnology: Electromedical & Electrotherapeutic Apparatus

Market Capitalization: 3.33 M

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 0.05 Change: -0 (-7.52%)
Ext. hours: Change: 0 (0%)

chart ETRM

Refresh chart

Strongest Trends Summary For ETRM

ETRM is in the long-term down -100% below S&P in 16 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: EnteroMedics Inc., a development stage medical device company, focuses on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases, and other gastrointestinal disorders. Its proprietary neuroblocking technology is designed to intermittently block the vagus nerve using electrical impulses. It develops the Maestro System, which limit the expansion of the stomach, control hunger sensations between meals, reduce the frequency and intensity of stomach contractions, and produce a feeling of early and prolonged fullness. The company is evaluating the Maestro System in human clinical trials in the United States, Australia, Mexico, and Norway. EnteroMedics Inc. has collaboration with Mayo Clinic for the development and testing of products for the treatment of obesity. The company was formerly known as Beta Medical, Inc. and changed its name to EnteroMedics Inc. in 2003. EnteroMedics Inc. was founded in 2002 and is headquartered in St. Paul, Minnesota.

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding9.25 M EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV0.46 Price/Cash Per Share
Price/Free Cash Flow-0.17 ROA-185.34% ROE-363.28% ROI
Current Ratio1.85 Quick Ratio1.69 Long Term Debt/Equity Debt Ratio0.96
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities5.45 M Cash From Investing Activities-20 K Cash From Operating Activities-5.62 M Gross Profit
Net Profit-7.17 M Operating Profit-6.96 M Total Assets14.34 M Total Current Assets13.02 M
Total Current Liabilities7.02 M Total Debt1.99 M Total Liabilities7.02 M Total Revenue
Technical Data
High 52 week27.7 Low 52 week1.72 Last close2.05 Last change0%
RSI52.17 Average true range0.33 Beta0.62 Volume16.46 M
Simple moving average 20 days4.33% Simple moving average 50 days7.27% Simple moving average 200 days-57.85%
Performance Data
Performance Week-8.48% Performance Month0.99% Performance Quart-52.87% Performance Half-50.6%
Performance Year-72.16% Performance Year-to-date2.5% Volatility daily4.98% Volatility weekly11.13%
Volatility monthly22.81% Volatility yearly79.03% Relative Volume134.2% Average Volume974.11 K
New High New Low-9%

News

2019-05-21 12:31:05 | Edited Transcript of ETRM earnings conference call or presentation 20-May-19 8:30pm GMT

2019-04-02 02:33:01 | Edited Transcript of ETRM earnings conference call or presentation 1-Apr-19 8:30pm GMT

2018-11-15 07:27:44 | Edited Transcript of ETRM earnings conference call or presentation 14-Nov-18 9:30pm GMT

2018-08-14 19:40:28 | Edited Transcript of ETRM earnings conference call or presentation 14-Aug-18 8:30pm GMT

2018-05-19 04:17:55 | Edited Transcript of ETRM earnings conference call or presentation 14-May-18 8:30pm GMT

2017-11-16 05:15:00 | EnteroMedics reports 3Q loss

2017-11-14 18:24:38 | Edited Transcript of ETRM earnings conference call or presentation 14-Nov-17 9:30pm GMT

2017-11-02 08:08:12 | Zacks.com highlights: Avon Products, Altria Group, EnteroMedics, Macquarie Infrastructure and Sibanye Gold

2017-10-25 08:21:12 | Express Scripts ESRX Q3 Earnings In Line, FY17 View Up

2017-10-23 08:30:00 | EnteroMedics Announces Name Change to ReShape Lifesciences Inc. NASDAQ: RSLS

2017-10-20 10:32:02 | athenahealth ATHN Beats Earnings, Misses Revenues in Q3

2017-10-17 08:00:00 | Today's Research Reports on Trending Tickers: EnteroMedics and Ionis Pharmaceuticals

2017-10-16 08:00:00 | EnteroMedics Announces Presentations at ObesityWeek 2017

2017-10-12 16:46:00 | EnteroMedics Announces New Employee Inducement Option Grants

2017-10-09 08:24:12 | The Zacks Analyst Blog Highlights: Thermo Fisher Scientific, SeaSpine Holdings and EnteroMedics

2017-10-06 15:27:07 | 4 Momentum Stocks That May Survive the Health Policy Mess

2017-10-04 08:10:00 | Today's Research Reports on Stocks to Watch: Mannkind and EnteroMedics

2017-10-03 18:14:01 | [$$] ReShape Owners to Receive Board Seats in EnteroMedics Deal

2017-10-03 08:30:00 | EnteroMedics Announces Acquisition Of ReShape Medical

2017-09-12 08:30:00 | EnteroMedics to Present at the Ladenburg Thalmann 2017 Healthcare Conference

2017-09-12 06:34:10 | Who Says Rising P/E Is Risky? 5 Top Stocks That Deny

2017-09-11 20:27:15 | Should You Buy EnteroMedics Inc ETRM?

2017-09-05 16:15:00 | EnteroMedics Begins Post-Approval Study for the Treatment of Obesity with vBloc Therapy

2017-09-01 11:12:03 | Community Health System Divests Hospitals to Lower Debts

2017-08-28 16:05:00 | Study Concludes Vagal Nerve Blocking with EnteroMedics' vBloc Therapy is Cost-Effective

2017-08-24 10:48:50 | EnteroMedics, Inc. :ETRM-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017

2017-08-21 09:00:00 | EnteroMedics Announces First Veterans Choice Program vBloc® Implant at MedStar Health in Maryland

2017-08-16 09:00:00 | EnteroMedics Announces Presentations Highlighting vBloc and Gastric Vest at IFSO Annual Conference

2017-08-14 08:10:00 | Today's Research Reports on Stocks to Watch: EnteroMedics and Aterna Zentaris

2017-08-11 08:20:00 | EnteroMedics Announces Pricing of $20 Million Underwritten Public Offering

2017-08-10 16:34:00 | EnteroMedics Announces Proposed Underwritten Public Offering

2017-08-08 13:42:51 | Edited Transcript of ETRM earnings conference call or presentation 8-Aug-17 3:30pm GMT

2017-08-08 08:40:00 | Investor Network: EnteroMedics Inc. to Host Earnings Call

2017-08-08 07:35:01 | EnteroMedics reports 2Q loss

2017-08-08 07:00:00 | EnteroMedics Announces Second Quarter 2017 Financial Results

2017-08-02 07:00:00 | EnteroMedics To Discuss Business Strategy And Financial Results For The Second Quarter Of 2017

2017-07-31 07:00:00 | EnteroMedics Receives Approval for Gastric Vest System Clinical Study in Spain

2017-07-25 07:00:00 | EnteroMedics Announces First Veterans Choice Program vBloc® Implant for Obesity at Methodist Dallas Medical Center

2017-07-20 07:00:00 | EnteroMedics Announces Receipt of European Patent Certificate

2017-06-28 07:00:00 | EnteroMedics Announces Affordable vBloc® Therapy Program for Weight Loss Patients

2017-06-26 07:00:00 | EnteroMedics Added to Russell Microcap® Index

2017-06-21 07:00:00 | EnteroMedics Announces vBloc Therapy to be Presented by Keynote Speaker at Major International Obesity Conference

2017-06-07 14:57:24 | Edited Transcript of ETRM earnings conference call or presentation 7-Mar-17 4:00pm GMT

2017-06-02 09:45:38 | EnteroMedics, Inc. :ETRM-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017

2017-05-31 07:00:00 | EnteroMedics Announces First vBloc® Neurometabolic Therapy Implant at AMITA Health Adventist Medical Center Bolingbrook

2017-05-24 14:00:01 | EnteroMedics snaps up maker of obesity 'vest'

2017-05-23 07:00:00 | EnteroMedics Announces the Acquisition of the Gastric Vest System

2017-05-18 07:00:00 | EnteroMedics Announces First vBloc® Neurometabolic Therapy Implant at McGuire Veterans Affairs Medical Center

2017-05-16 13:10:53 | Edited Transcript of ETRM earnings conference call or presentation 16-May-17 12:30pm GMT

2017-05-16 07:10:39 | EnteroMedics reports 1Q loss